7 thoughts on “C-19 Chat Post – August 26 2022”

  1. Thanks TK.

    Pfizer’s Covid-19 pill plaxavoid has been proven ineffective in people under 65 years of age.

    Back to the drawing board?

    1. Yes …sadly. Faust addressed this in his email today.

      Who benefits from Paxlovid? Any Covid-19 patient with a pre-existing medical condition placing them at high risk of severe disease who has not been vaccinated should almost certainly take Paxlovid. Among people with prior immunity (either from infection or vaccination), older people appear to benefit, though a lot less, since the rate of hospitalization and death in these people is already so much lower. Meanwhile, a recent observational study did not detect any association between Paxlovid and better outcomes among people ages 40-64, regardless of vaccination status (and they didn’t bother checking any younger).

Comments are closed.